Journal of Clinical and Translational Hepatology

Journal Information
ISSN / EISSN : 22250719 / 23108819
Current Publisher: Xia & He Publishing Inc. (10.14218)
Total articles ≅ 277
Current Coverage
PUBMED
PMC
ESCI
Archived in
SHERPA/ROMEO
Filter:

Latest articles in this journal

Anjing Zhu, Xinzhong Liao, Shuang Li, Hang Zhao, Limin Chen, Min Xu, Xiaoqiong Duan
Journal of Clinical and Translational Hepatology, Volume 7, pp 1-5; doi:10.14218/jcth.2018.00054

Lai Wei, Jia Shang, Yuanji Ma, Xiaoyuan Xu, Yan Huang, Yujuan Guan, Zhongping Duan, Wenhong Zhang, Zhiliang Gao, Mingxiang Zhang, et al.
Journal of Clinical and Translational Hepatology, Volume 7, pp 1-5; doi:10.14218/jcth.2019.00018

Marko Duvnjak, Sanja Stojsavljević, Lucija Virović Jukić, Lea Smirčić Duvnjak
Journal of Clinical and Translational Hepatology, Volume 7, pp 97-98; doi:10.14218/JCTH.2019.00022

Leon D. Averbukh, David C. Wu, Woo Cheal Cho, George Y. Wu
Journal of Clinical and Translational Hepatology, Volume 7, pp 149-153; doi:10.14218/JCTH.2019.00017

Abstract:Biliary mucinous cystadenomas are cystic neoplasms commonly mistaken for simple cysts. They are rare and generally benign tumors, often incidentally found on imaging and during unrelated surgical interventions. They tend to be slow growing though may reach symptomatic dimensions. Misdiagnosis of biliary mucinous cystadenomas may have serious consequences secondary to their potential for malignant transformation into biliary mucinous cystadenocarcinomas. Here, we review the epidemiology, etiology, pathology, diagnostic modalities, histology, and available treatment methods for mucinous cystadenomas reported in current literature.
Matthew Wu, Michael Schuster, Micheal Tadros
Journal of Clinical and Translational Hepatology, Volume 7, pp 154-164; doi:10.14218/JCTH.2018.00057

Abstract:The clinical management of portal vein thrombosis (PVT) remains ambiguous due to its heterogeneous presentations and its associations with liver disease, malignancy, and hypercoagulable states. The natural history and clinical outcome of PVT are highly variable, dependent upon size, extent and degree of the thrombotic occlusion, as well as the physiological impact of patient comorbidities. While existing clinical guidelines consistently recommend low molecular weight heparin or vitamin K antagonist anticoagulation in cirrhotic patients with symptomatic acute PVT, management of asymptomatic and chronic PVT may need to be determined on a case-by-case basis, factoring in the state of underlying liver disease. In general, patients with PVT and underlying malignancy should be anticoagulated to alleviate symptoms and prevent recurrences that could disrupt the cancer management. However, existing clinical data does not support routine anticoagulation of cirrhotic patients with asymptomatic PVT in the absence of underlying cancer. While low molecular weight heparin and vitamin K antagonist remain the most commonly used agents in PVT, an emerging body of clinical evidence now suggests that direct-acting oral anticoagulants may be used safely and effectively in PVT. As such, direct-acting oral anticoagulants may offer a more convenient anticoagulation alternative for PVT management in future practice.
Haruka Hirono, Kazuhiko Watanabe, Katsuhiko Hasegawa, Shogo Ohkoshi
Journal of Clinical and Translational Hepatology, Volume 7, pp 127-131; doi:10.14218/JCTH.2018.00048

Abstract:Background and Aims: Fatty infiltration of liver may induce insulin resistance (IR), and a proportion of patients with nonalcoholic fatty liver disease (NAFLD) is diagnosed with nonalcoholic steatohepatitis. Transient elastography is gaining popularity as a means of non-invasively determining both liver stiffness (fibrosis level) and degree of fatty infiltration, expressed as controlled attenuation parameter (CAP) value.
Natthiya Pholmoo, Chalermrat Bunchorntavakul
Journal of Clinical and Translational Hepatology, Volume 7, pp 132-139; doi:10.14218/JCTH.2018.00066

Abstract:Background and Aims: Acetaminophen (APAP) is the leading cause of drug overdose and hepatotoxicity worldwide, including in Thailand. Patterns of overdose and hospital management are known to have significant impacts on the outcomes of APAP overdose, and these factors vary from country to country. Therefore, this study aimed to analyze clinical characteristics of Thai patients with APAP overdose in terms of overdose patterns, clinical presentation, treatment and outcomes.
Bin Chen, Long Pang, Hao-Bin Chen, Dong-Bo Wu, Yong-Hong Wang, En-Qiang Chen
Journal of Clinical and Translational Hepatology, Volume 7, pp 1-6; doi:10.14218/jcth.2019.00007

Saibal Das, Kirubakaran Ramakrishnan, Sapan Kumar Behera, Mahalakshmi Ganesapandian, Alphienes Stanley Xavier, Sandhiya Selvarajan
Journal of Clinical and Translational Hepatology, Volume 7, pp 165-171; doi:10.14218/JCTH.2018.00037

Abstract:Hepatitis B virus (HBV) immunization is safe and has been accepted worldwide as a routine practice. The target of such vaccination is to induce the immune response in the host, resulting in the prevention of replication of HBV. There are several immunological and clinical factors which determine the clinical efficacy and safety of the HBV vaccine. In this article we have highlighted the response of the host immune system to HBV vaccination (immunogenicity), efficacy, and safety of the vaccine, issues with booster dosing, paths of development (preclinical and clinical) of the HBV vaccine, novel and upcoming strategies for improvement of HBV vaccination, and the concept of therapeutic HBV vaccination. The different aspects and regulatory recommendations pertaining to HBV vaccine development are also discussed. The new strategies for improvement of HBV vaccination include pre-S1 and pre-S2 portions of the HBV surface antigen, increasing the antigen dose, accelerated vaccination schedules, alternative vaccination route, use of adjuvants like immunostimulatory DNA sequences, etc. Therapeutic vaccination is being explored for initiation of a multifunctional and multispecific T cell response against the major HBV antigens and also effective activation of humoral immunity for viral control.
Nikhil Kapila, Kawtar Al Khalloufi, Gianina Flocco, K.V. Narayanan Menon, Christina Lindenmeyer, Diego Reino, Jason M. Vanatta, Samer Ebaid, Andreas Tzakis, Xaralambos Bobby Zervos
Journal of Clinical and Translational Hepatology, Volume 7, pp 122-126; doi:10.14218/JCTH.2019.00014

Abstract:Background and Aims: Hepatitis C virus (HCV)-infected organs are underutilized. We aimed to assess the safety and efficacy of direct-acting antiviral agents (DAAs) therapy in HCV viremic patients who are transplanted with a liver from a HCV viremic donor.